Related Experiment Video
Updated: Mar 29, 2026
07:52
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
20.7K
Update in large cell lymphoma: understanding the pathology report
1Cleveland Clinic Lerner College of Medicine, Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH.
Hematology. American Society of Hematology. Education Program
|December 6, 2015
Summary
Diagnosing diffuse aggressive large B-cell lymphomas presents challenges due to complex criteria and biological uncertainties. This review clarifies diagnostic difficulties and biomarker assessment in these B-cell malignancies.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Diffuse aggressive large B-cell lymphomas (DLBCL) are a diverse group of B-cell cancers.
- Accurate diagnosis is crucial but complicated by diagnostic criteria, biological understanding gaps, and technological limitations.
Purpose of the Study:
- To review the pathological features of specific DLBCL subtypes within the WHO 2008 classification.
- To highlight diagnostic challenges and biomarker assessment difficulties in DLBCL.
Main Methods:
- Review of pathological features of DLBCL subtypes.
- Discussion of diagnostic criteria and biomarker assessment limitations.
Main Results:
- Identified areas of diagnostic uncertainty in DLBCL classification.
- Highlighted challenges in biomarker assessment for these lymphomas.
Conclusions:
- Improved understanding of DLBCL biology and diagnostic limitations can enhance pathologist-clinician communication.
- Addressing diagnostic ambiguities is essential for accurate patient management.
